Cargando…

Anti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer

Capecitabine (CAP) is a 5-FU pro-drug approved for the treatment of several cancers and it is used in combination with gemcitabine (GEM) in the treatment of patients with pancreatic adenocarcinoma (PDAC). However, limited pre-clinical data of the effects of CAP in PDAC are available to support the u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Courtin, Aurélie, Richards, Frances M., Bapiro, Tashinga E., Bramhall, Jo L., Neesse, Albrecht, Cook, Natalie, Krippendorff, Ben-Fillippo, Tuveson, David A., Jodrell, Duncan I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3696095/ https://www.ncbi.nlm.nih.gov/pubmed/23840665 http://dx.doi.org/10.1371/journal.pone.0067330

Ejemplares similares

SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice
por: Neesse, Albrecht, et al.
Publicado: (2014)

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo
por: Bapiro, T E, et al.
Publicado: (2014)

Understanding the Complexity of Porous Graphitic Carbon (PGC) Chromatography: Modulation of Mobile-Stationary Phase Interactions Overcomes Loss of Retention and Reduces Variability
por: Bapiro, Tashinga E., et al.
Publicado: (2016)

A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS: comparison with (19)F NMR spectroscopy
por: Bapiro, Tashinga E., et al.
Publicado: (2011)

Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma
por: Cook, Natalie, et al.
Publicado: (2012)

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
por: Lin, Y, et al.
Publicado: (2012)

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
por: Jacobetz, Michael A, et al.
Publicado: (2013)

Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma
por: Neesse, Albrecht, et al.
Publicado: (2013)

Editorial: Metabolism of anti-cancer drugs: Interplay involving pharmacology and pharmacokinetics
por: Bapiro, Tashinga E., et al.
Publicado: (2022)

SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer
por: Ramu, Iswarya, et al.
Publicado: (2019)

Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling
por: Krippendorff, Ben-Fillippo, et al.
Publicado: (2012)

Combenefit: an interactive platform for the analysis and visualization of drug combinations
por: Di Veroli, Giovanni Y., et al.
Publicado: (2016)

Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis
por: Krippendorff, Ben-Fillippo, et al.
Publicado: (2009)

Anti-Tumour Effects of a Specific Anti-ADAM17 Antibody in an Ovarian Cancer Model In Vivo
por: Richards, Frances M., et al.
Publicado: (2012)

An automated fitting procedure and software for dose-response curves with multiphasic features
por: Veroli, Giovanni Y. Di, et al.
Publicado: (2015)

Anti‐stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma
por: Carapuça, Elisabete F, et al.
Publicado: (2016)

Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report
por: Connell, Claire M., et al.
Publicado: (2020)

T Cell–Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer
por: Li, Dandan, et al.
Publicado: (2021)

Depletion of Macrophages Improves Therapeutic Response to Gemcitabine in Murine Pancreas Cancer
por: Buchholz, Soeren M., et al.
Publicado: (2020)

Cytosolic 5′-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites
por: Patzak, Melanie S., et al.
Publicado: (2019)

Stromal Features of the Primary Tumor Are Not Prognostic in Genetically Engineered Mice of Pancreatic Cancer
por: Hasselluhn, Marie C., et al.
Publicado: (2019)

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours
por: Medley, L, et al.
Publicado: (2011)

A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer
por: Kollmorgen, Gwendlyn, et al.
Publicado: (2017)

The microbiome in pancreatic diseases: Recent advances and future perspectives
por: Ammer-Herrmenau, Christoph, et al.
Publicado: (2020)

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer
por: Hessmann, E, et al.
Publicado: (2018)

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
por: Cook, Natalie, et al.
Publicado: (2018)

Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer
por: Ji, Jeong-Seon, et al.
Publicado: (2010)

Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
por: Devata, Sumana, et al.
Publicado: (2012)

Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma
por: Al-Sukhun, Sana, et al.
Publicado: (2023)

G-Quadruplex DNA as a Molecular Target for Induced Synthetic Lethality in Cancer Cells
por: McLuckie, Keith I. E., et al.
Publicado: (2013)

Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer
por: Goetze, Robert G., et al.
Publicado: (2019)

Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models
por: Dunlop, Charles R., et al.
Publicado: (2020)

GEMMs as preclinical models for testing pancreatic cancer therapies
por: Gopinathan, Aarthi, et al.
Publicado: (2015)

Waging war against pancreatic cancer: an interview with David Tuveson
por: Tuveson, David
Publicado: (2017)

Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma
por: SAIF, MUHAMMAD WASIF, et al.
Publicado: (2014)

Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer
por: Kim, Yeon-Joo, et al.
Publicado: (2013)

Pancreatic cancer SLUGged
por: Josselsohn, Rachel H., et al.
Publicado: (2020)

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2008)

Size-tuneable and immunocompatible polymer nanocarriers for drug delivery in pancreatic cancer
por: Popov, Andrea Bistrović, et al.
Publicado: (2022)

Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
por: Middleton, Gary, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_prp57pftvprp7o35jkbae39im7